Understanding how lung cancer changes its cell type to resist treatment
Official title: Project 2 - Epigenetic Drivers of Lineage Plasticity in Lung Cancer
Funded at Dana-Farber Cancer Inst · NIH-11016330 · Data updated 2026-11-12
This study is looking at how some lung cancers can change from one type to another when treated, and it's for people with lung cancer who want to understand why their tumors might not respond to therapy; researchers are using special techniques to see how certain genes play a role in this change.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $594,494 |
| NIH project number | 1P01CA295524-01 |
| Project ID | NIH-11016330 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with small cell lung cancer or lung adenocarcinoma who may be experiencing treatment resistance.
✕Less likely to help
Patients with other types of cancer or those whose lung cancer is not resistant to current therapies may not benefit from this research.
What this research studies
This research investigates the mechanisms behind lineage plasticity in lung cancer, particularly how certain lung cancer types can change from small cell lung cancer (SCLC) to lung adenocarcinoma (LUAD) in response to therapies. Using advanced genetic techniques, the study aims to identify the role of the epigenetic modifier EED in this transformation process. By creating genetically engineered mouse models, researchers will explore how changes at the genetic level influence tumor behavior and resistance to treatment. This work could provide insights into the tumor microenvironment and how it affects cancer progression.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that effectively target the mechanisms of resistance in lung cancer.
How similar studies have gone: Previous research has shown promising results in understanding lineage plasticity in cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Oser, Matthew Gilbert — Dana-Farber Cancer Inst
- Study coordinator: Oser, Matthew Gilbert
Related research
Other NIH-funded projects on the same topics.
-
Blood-based markers to identify lung cancer risk in never-smokers
A researchers team at NYU School of Medicine is testing blood tests that might flag higher lung cancer risk in people who have never smoked, helping decide who might need screening.
-
Integrative Analysis of Lung Cancer Risk and Its Causes
A large, multi-part study at the University of New Mexico is exploring why lung cancer happens and how to better prevent and detect it.
-
Integrative Analysis of Lung Cancer Risk and Causes
A large NIH project is exploring how tobacco use, behavior, biology, and screening practices influence lung cancer risk and outcomes to help prevent and detect it earlier.
-
Digital health strategies to expand lung cancer screening in safety-net clinics
A funded project aims to help low-resource clinics increase the use of lung cancer screening for patients who smoke or are at risk.
-
Proteomics-guided matching of lung cancer tumors to preclinical models
This grant aims to improve how we match a patient’s lung cancer tumor to the right preclinical models using protein data.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.